Seagen (SGEN) FY 2020 Annual General Meeting April 29, 2025 04:09 PM ET Speaker0 Good day and welcome to the Seattle Genetics twenty twenty Annual Meeting of Shareholders. Today's meeting is being recorded. Towards the ending of the meeting we'll have a question and answer session. You can submit questions or comments at any time by clicking on the message icon. It is now my pleasure to turn today's meeting over to Clay Segal, Chairman, President and Chief Executive Officer. Doctor. Segal, please go ahead. ...

Core Insights - Tonix Pharmaceuticals is advancing TNX-1700, a combination therapy involving TFF2 and anti-PD1 antibody, showing potential in enhancing anti-tumor immune responses in gastric and colorectal cancers [1][2] - The company presented promising preclinical data at the AACR 2025 Annual Meeting, indicating that TFF2-mediated CXCR4 partial agonism is more effective than antagonism in reducing gastric cancer in animal models [1][2] Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company with a focus on developing therapies for pain management, immunology, and infectious diseases [7] - The company is also working on TNX-102 SL for fibromyalgia, which has received Fast Track designation from the FDA, with a PDUFA goal date of August 15, 2025 [7] Research and Development - TNX-1700 is being developed under a license from Columbia University, with Dr. Timothy Wang as the inventor, who has demonstrated the protective role of TFF2 against cancer development [3] - The research indicates that TFF2 can suppress immunosuppressive neutrophils (PMN-MDSCs) and enhance the activation of CD8+ T cells, which are crucial for anti-tumor immunity [2][3] Clinical Implications - The combination of TFF2 and anti-PD1 therapy has shown promise in reducing immunosuppression in the tumor microenvironment, potentially leading to improved treatment outcomes for patients with gastric cancer [2] - The correlation between TFF2 levels and PMN-MDSCs in gastric cancer patients suggests a potential biomarker for treatment efficacy [2]

Things were going great, right until the point when they weren't.Few would dispute that Pfizer (PFE 0.63%) is an icon within the pharmaceutical world. And, giving credit where it's due, the drugmaker largely led the charge against the COVID-19 pandemic with both a vaccine and treatment.Anyone keeping tabs on this ticker of late, however, likely knows it's also been a disappointment since its contagion-driven peak. Indeed, thanks to more than a 60% pullback from its late-2021 high, investors that committed $ ...

- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash balance and investment balance of $624.3 million as of March 31, 2025 expected to provide runway through 2027 WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new ...

– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today ...

FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE April 30, 2020 Julie, treated for metastatic breast cancer on a TUKYSA clinical trial Transformative therapies | Targeting cancer 1 Transformative Therapies | Targeting Cancer | Overview and Key Highlights | Clay Siegall, Ph.D., President & CEO | | --- | --- | | Commercial | Chip Romp, EVP, Commercial | | Financial | Todd Simpson, CFO | | Research & Development | Roger Dansey, M.D., CMO | 2 Forward-Looking Statements Certain of the statements made in ...

Julie, treated for metastatic breast cancer on a TUKYSA clinical trial Transformative therapies | Targeting cancer 1 Transformative Therapies | Targeting Cancer Today's Agenda SECOND QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE July 30, 2020 3 . CLAY SIEGALL, Ph.D. President and CEO | INTRODUCTION | Peggy Pinkston, VP, Investor Relations | | --- | --- | | CEO OPENING REMARKS | Clay Siegall, Ph.D., President & CEO | | COMMERCIAL UPDATE | Chip Romp, EVP, Commercial U.S. | | FINANCIAL RESULTS & GUIDANCE ...

Core Viewpoint - Radiopharm Theranostics has initiated a Phase 2b clinical trial for 18F-RAD101, aimed at improving diagnostic accuracy for suspected recurrent brain metastases from solid tumors, highlighting the company's commitment to innovative oncology radiopharmaceuticals [1][4]. Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, listed on ASX (RAD) and NASDAQ (RADX) [5]. - The company has a diverse pipeline that includes one Phase 2 and three Phase 1 trials targeting various solid tumors, including lung, breast, and brain cancers [5]. Clinical Trial Details - The Phase 2b trial is a multicenter, open-label, single-arm study evaluating the diagnostic performance of 18F-RAD101 in 30 patients with confirmed recurrent brain metastases from different solid tumors [2]. - The primary objective is to assess the concordance between 18F-RAD101 positive lesions and those identified through conventional imaging methods, specifically MRI with gadolinium [2]. Technology and Innovation - 18F-RAD101 is a novel imaging small molecule that targets fatty acid synthase (FASN), which is overexpressed in many solid tumors, including cerebral metastases, allowing for accurate cancer cell detection [3]. - Positive results from a previous Phase 2a trial at Imperial College London indicated significant tumor uptake of 18F-RAD101, consistent across different tumor origins [3]. Market Potential - The trial aims to enhance diagnostic precision for over 300,000 patients diagnosed with brain metastases annually in the U.S., addressing the limitations of current imaging techniques in distinguishing between tumor recurrence and radiation necrosis [4].

Compelling Phase 1 safety and efficacy data for FAP-Dox (AVA6000) with preliminary evidence of efficacy in salivary gland cancers and no severe cardiac toxicity Progression free survival (PFS) data to date represents a near doubling of the benchmarking data in this patient population without reaching median PFS LONDON and PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-t ...

Core Viewpoint - Gilead Sciences, Inc. reported disappointing first-quarter 2025 results, with adjusted earnings per share (EPS) of $1.81 and total revenues of $6.7 billion, both missing consensus estimates [1][2][3] Financial Performance - Adjusted EPS of $1.81 missed the Zacks Consensus Estimate by a penny, compared to a loss per share of $1.32 in the same quarter last year [1] - Total revenues of $6.7 billion were flat year over year and missed the Zacks Consensus Estimate of $6.8 billion [1] - Total product sales decreased 1% year over year to $6.6 billion, while excluding Veklury, product sales increased 4% to $6.3 billion [3] Product Sales Breakdown - HIV product sales grew 6% year over year to $4.6 billion, exceeding both the Zacks Consensus Estimate and model estimate of $4.5 billion [3] - Biktarvy sales increased 7% year over year to $3.15 billion but missed the Zacks Consensus Estimate of $3.2 billion [4] - Descovy sales surged 38% year over year to $586 million, beating the Zacks Consensus Estimate of $479 million [5] - Liver Disease portfolio sales rose 3% to $758 million, driven by higher demand for HBV and HDV drugs [6] - Veklury sales plummeted 45% to $302 million, missing the Zacks Consensus Estimate of $387 million [7] - Cell Therapy product sales decreased 3% to $464 million, missing the Zacks Consensus Estimate of $491 million [7] Cost and Margin Analysis - Adjusted product gross margin slightly increased to 85.5% from 85.4% in the year-ago quarter [11] - Research and development expenses totaled $1.3 billion, down from $1.4 billion in the previous year [11] - SG&A expenses amounted to $1.2 billion, down from $1.3 billion [11] Dividend and Guidance - Gilead declared a quarterly dividend of $0.79 per share for Q2 2025, payable on June 27, 2025 [12] - The company reiterated its 2025 guidance, projecting product sales between $28.2 billion and $28.6 billion, with adjusted EPS anticipated in the range of $7.70-$8.10 [13] Pipeline Updates - The FDA accepted new drug application submissions for lenacapavir for HIV prevention, with a target action date of June 19, 2025 [14] - Gilead received conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis [14] Overall Performance Assessment - Gilead's first-quarter results were disappointing, particularly due to a decline in oncology drugs affecting revenue growth [15] - Despite challenges, Biktarvy maintained its dominant position in the HIV market, and Descovy showed strong performance [15] - The potential approval of lenacapavir could further strengthen Gilead's HIV franchise amid increasing competition [16]